Clinical cardiac PET: quo vadis?
Clinical cardiac PET: quo vadis?
复制标题
临床心脏 PET：现状如何？
DOI：
10.1007/bf02939982
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
Maddahi,J
中科院分区：
文献类型：
--
作者：
Schelbert,HR;Maddahi,J
对心脏正电子发射断层扫描（PET）的未来进行评估，充其量是具有挑战性的。过去往往是未来的前奏。然而，当前医疗行业迅速而前所未有的变化可能会限制过去的推断。正在发挥作用的力量可能会深刻地改变私营和公共部门的医疗保健服务。事实上，它们可能会开启医学的“工业化”。类似的力量影响着研究环境，成为新诊断和治疗方法启动、发展和成熟的关键因素。与此同时，变化孕育机遇。在评估心脏PET未来的临床作用时，重要的是要列举其主要优点和局限性。它的优点之一是可获得几乎无限数量的放射性示踪剂和高时间和空间分辨率。两者都是它能够以绝对单位提供区域功能过程测量的关键成分。限制包括技术和后勤复杂性以及目前高昂的启动和运营成本。PET的优点和局限性无疑将影响其临床应用前景。
An assessment of what the future holds for cardiac positron emission tomography (PET) is, at best, challenging. Often the past is a prelude to the future. Yet the current rapid and unprecedented changes in the medical enterprise might limit extrapolations from the past. The forces at work might profoundly alter the delivery of health care in both the private and the public sectors. Indeed, they might usher in the" industrialization" of medicine. Similar forces affect the research environment as a critical element for the initiation, development, and maturation of new diagnostic and therapeutic approaches. At the same time, changes foster opportunities. In evaluating the future clinical role of cardiac PET, it is important to enumerate its main advantages and its limitations. Among its advantages are the availability of a virtually unlimited number of radiotracers and the high temporal and spatial resolution. Both are key ingredients for its ability to provide measurements of regional functional processes in absolute units. Limitations include technical and logistic complexities and the current high start-up and operational cost. Both advantages and limitations will undoubtedly affect the clinical future of PET.